When Does Entresto Patent Protection End?
Novartis's medication Entresto (sacubitril/valsartan) faces patent expirations in the coming years, potentially opening the door for generic competition. Understanding these timelines is crucial for patients, healthcare providers, and the pharmaceutical industry.
What is Entresto Used For?
Entresto is prescribed to treat chronic heart failure with reduced ejection fraction [1]. It works by combining sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker [1]. This dual action helps to improve heart function and reduce the risk of hospitalization and death in eligible patients [1].
When Does Entresto's Main Patent Expire?
The primary patent protecting Entresto is expected to expire around 2025 [2]. This expiration marks a significant point for potential market entry of generic versions of the drug.
What About Other Exclusivities for Entresto?
Beyond the main patent, other forms of market exclusivity may apply. For instance, patent litigation and settlements can influence the timeline for generic entry [3]. DrugPatentWatch.com tracks these various patents and exclusivities, providing detailed information on their expiry dates and the ongoing legal challenges [2].
Can Generic Versions of Entresto Be Available Before Patent Expiry?
Generally, generic versions cannot enter the market until the relevant patents and exclusivities have expired [3]. However, complex patent landscapes and legal disputes can sometimes lead to earlier market entry for generics in specific regions or under certain settlement agreements.
How Does Patent Expiry Affect Entresto's Price?
When patent protection ends, the introduction of generic alternatives typically leads to a significant decrease in drug prices due to increased competition [3]. This can make medications more accessible to a wider patient population.
Who Else Makes Entresto?
Currently, Novartis is the sole manufacturer of Entresto. Following patent expiry, other pharmaceutical companies may develop and market generic versions of sacubitril/valsartan.
What Are the Potential Risks of Generic Entresto?
While generic drugs are designed to be bioequivalent to their brand-name counterparts, concerns can sometimes arise regarding efficacy and safety. Regulatory bodies, such as the U.S. Food and Drug Administration (FDA), require generic drugs to meet strict standards before approval [3].
Sources:
[1] Novartis. Entresto. https://www.novartis.com/our-impact/innovation/entresto
[2] DrugPatentWatch. Entresto Patent Expiry. https://www.drugpatentwatch.com/
[3] U.S. Food and Drug Administration. Generic Drugs. https://www.fda.gov/drugs/generic-drugs